Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.

Journal of translational medicine - 31 May 2022

Cheng Lei, Wang Yanan, Qiu Lixin, Chang Yuanyuan, Lu Haijiao, Liu Chenchen, Zhang Bo, Zhou Yan, Bai Hao, Xiong Liwen, Zhong Hua, Nie Wei, Han Baohui

Abstract excerpt

BACKGROUND: mTOR pathway is known to promote cancer malignancy and influence cancer immunity but is unknown for its role in immune checkpoint inhibitors (ICI) therapy. METHODS: Using Memorial Sloan-Kettering Cancer Center dataset (MSKCC), we extracted mTOR pathway gene mutations for stepwise Cox regression in 1661 cancer patients received ICI. We associated the mutation of the gene signature resulted from the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Neoplasms

Share to PI3K/AKT/mTOR signaling in cancer

Share to Renal cell carcinoma treatment

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 35642038
DOI: 10.1186/s12967-022-03436-1
PMCID: PMC9153162

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.PMID 35642038Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

TLR4 exhibits a Pivotal Role in Immuno-Oncology through Systematic Pan-Cancer AnalysisSemantic proximity Read ↗

A Transcriptomic Meta-Analysis Identifies Differentially Expressed Genes across Different Types of Cancer and Their Association with Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsSemantic proximity Read ↗

BRAF mutation predicts survival after immunotherapy across multiple cancer types.Semantic proximity Read ↗

Pan-Cancer Analysis Reveals RIPK2 Predicts Prognosis and Promotes Immune Therapy Resistance Via Triggering Cytotoxic T Lymphocytes DysfunctionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.